Requests that FDA determine whether RASUVO (methotrexate) Injection, 27.5 mg/0.55 mL (27.5 mg/0.55 mL), approved under New Drug Application (“NDA”) number 205776, held by Medexus Pharma Inc., has been voluntarily withdrawn for reasons of safety or effectiveness